Navigation Links
New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/16/2008

BRIDGEWATER, N.J., May 16 /PRNewswire/ -- Data from three studies evaluating associations between lower mean baseline hemoglobin (Hb) levels and the rate of blood transfusions, as well as the possible effect of restrictions on reimbursement for erythropoiesis-stimulating agents (ESAs) in Medicare patients on the nation's blood supply, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting later this month. The meeting will take place in Chicago from May 30 to June 3, 2008.

Data from the following studies will be presented:

Transfusion Outcomes in Erythropoiesis-Stimulating Agent (ESA)-Treated Cancer Chemotherapy Patients Based on Achieved Hemoglobin (Hb) Levels

Kay Larholt, Sc.D., Abt Associates, Lexington, MA

Presentation: Health Svcs Research, Sunday, June 1, 2008; 8:00am - 12:00pm CST, S Hall A1

Abstract Number: 6637

Last year, the Centers for Medicare and Medicaid Services (CMS) implemented a National Coverage Determination (NCD) largely eliminating coverage for non-renal ESA administration when patients have hemoglobin concentrations above 10 grams per deciliter of blood (g/dL). This study assessed the potential clinical implications of these policy changes by evaluating data from an ongoing prospective registry of ESA-treated patients in 55 U.S. oncology clinics between December 2003 and November 2007. Data were analyzed from 330 adult chemotherapy-treated oncology patients who had hemoglobin concentrations less than 10 g/dL prior to ESA administration and received two or more ESA doses. Transfusion-related outcomes were categorized based on mean Hb values achieved during ESA treatment into three cohorts: mean achieved Hb between 9.1 g/dL and 10 g/dL, between 10.1 g/dL and 11 g/dL, or between 11.1 g/dL and 12 g/dL.

Hematologic and Transfusion Outcomes Following Implementation of the Erythropoiesis-Stimulating Agent (ESA) National Coverage Determination (NCD) in Medicare Cance
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
3. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
4. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
5. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
6. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
9. Navigenics(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 Migranade, Inc. announced today the ... to the 36 million U.S. migraine sufferers November, 2014. ... targets the actual cause of migraines and not just ... not the source Migranade is assured to be a ... Relief is available at http://www.migranade.com and will ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
(Date:10/30/2014)... CHARLOTTETOWN , Oct. 30, 2014 /CNW/ - Atlantic ... three-year agreement reached between Canada,s ... Jim Keon , President of the Canadian Generic Pharmaceutical ... made the comments while speaking at the Atlantic Summit ... Charlottetown , which is being hosted by the ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... N.J., Aug. 1, 2011 Social stigma is the ... care physicians, according to a survey commissioned by Janssen ... the National Medical Association (NMA).(1) Despite the belief by ... very serious or a crisis in the African-American community, ...
... Reportlinker.com announces that a new market research ... Prefilled Syringes: Devices, Therapeutics, Players, ... http://www.reportlinker.com/p0581168/Prefilled-Syringes-Devices-Therapeutics-Players-Markets-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... continues to grow, the issue of prefilled ...
Cached Medicine Technology:Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 2Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 3Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 4Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 2Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects 3
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... have found that an active lifestyle with limiting TV time ... conducted in the US TV watching results in a lower ... games, reading, writing or driving a car. Prolonged TV watching ... are focussed on increasing exercise and hardly concentrate on reducing ...
... whether daily moderate exercise could actually prevent Heart disease. ... hiking, climbing stairs, racket sports and swimming does really ... disease. Recommendations in the United States and elsewhere say ... sufficient for good heart health.// A World Health Organization ...
... that mice lacking a specific immune cell are unable to ... (AHR) which is narrowing of the tiny passages in the ... mite. AHR is triggered by the immune system and leads ... attack. Researchers at Stanford University have been studying mice that ...
... health of their children most expecting moms will do whatever needs ... of rest. But are those moms who smoke, ready to set ... moms willing to put their habit on ,hold for the sake ... recent meeting of the Baxter County Tobacco Control Committee was ,that// ...
... particularly those who are breastfed, should be given vitamin D ... the bones fail to grow straight and strong. While breast ... contain enough vitamin D to meet babies needs. This happens ... of the vitamin D. All infant formula sold in the ...
... now studied a new electrical device,that might lead ... Parkinson's disease.,This new treatment involves implanting an electrical ... for Parkinson's patients. This,electrical device helps stimulate both ... otherwise cause disabling tremor. The researchers ran a ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: